Katsuhiro Imaki

523 total citations
12 papers, 438 citations indexed

About

Katsuhiro Imaki is a scholar working on Molecular Biology, Pharmacology and Pharmacology. According to data from OpenAlex, Katsuhiro Imaki has authored 12 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 4 papers in Pharmacology and 3 papers in Pharmacology. Recurrent topics in Katsuhiro Imaki's work include Inflammatory mediators and NSAID effects (4 papers), Enzyme function and inhibition (3 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). Katsuhiro Imaki is often cited by papers focused on Inflammatory mediators and NSAID effects (4 papers), Enzyme function and inhibition (3 papers) and Eicosanoids and Hypertension Pharmacology (3 papers). Katsuhiro Imaki collaborates with scholars based in Japan, Sweden and Bulgaria. Katsuhiro Imaki's co-authors include Masaaki Toda, Tsumoru Miyamoto, Kazuhito Kawabata, Mayumi Suzuki, Masafumi Sugitani, Fumio Hirata, Nobuhiko Nakazawa, Hisao Nakai, Masaki Hayashi and Masanori Kawamura and has published in prestigious journals such as Biochemical and Biophysical Research Communications, Bioorganic & Medicinal Chemistry and Chemical and Pharmaceutical Bulletin.

In The Last Decade

Katsuhiro Imaki

12 papers receiving 419 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katsuhiro Imaki Japan 8 106 105 101 80 61 12 438
John R. Feagler United States 10 150 1.4× 109 1.0× 46 0.5× 56 0.7× 35 0.6× 12 606
H. J. Reimers Canada 12 110 1.0× 81 0.8× 45 0.4× 39 0.5× 81 1.3× 23 567
Richard A. McReynolds United States 11 275 2.6× 130 1.2× 142 1.4× 32 0.4× 42 0.7× 14 854
Takuo Sato Japan 8 45 0.4× 129 1.2× 64 0.6× 27 0.3× 28 0.5× 15 413
Stefan Wohlfeil Germany 11 65 0.6× 141 1.3× 60 0.6× 22 0.3× 31 0.5× 18 581
Yuji Hitomi Japan 8 36 0.3× 164 1.6× 117 1.2× 22 0.3× 39 0.6× 15 550
Shozo Matsuoka Japan 9 242 2.3× 180 1.7× 190 1.9× 111 1.4× 23 0.4× 15 729
G Kōsaki Japan 15 77 0.7× 206 2.0× 49 0.5× 76 0.9× 30 0.5× 40 685
Evelyn Gaynor United States 7 52 0.5× 122 1.2× 91 0.9× 20 0.3× 28 0.5× 12 434
M Schönharting Germany 8 36 0.3× 180 1.7× 157 1.6× 18 0.2× 39 0.6× 17 447

Countries citing papers authored by Katsuhiro Imaki

Since Specialization
Citations

This map shows the geographic impact of Katsuhiro Imaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katsuhiro Imaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katsuhiro Imaki more than expected).

Fields of papers citing papers by Katsuhiro Imaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katsuhiro Imaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katsuhiro Imaki. The network helps show where Katsuhiro Imaki may publish in the future.

Co-authorship network of co-authors of Katsuhiro Imaki

This figure shows the co-authorship network connecting the top 25 collaborators of Katsuhiro Imaki. A scholar is included among the top collaborators of Katsuhiro Imaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katsuhiro Imaki. Katsuhiro Imaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

12 of 12 papers shown
2.
Imaki, Katsuhiro, et al.. (1996). Non-peptidic inhibitors of human neutrophil elastase: The design and synthesis of sulfonanilide-containing inhibitors. Bioorganic & Medicinal Chemistry. 4(12). 2115–2134. 27 indexed citations
3.
Kawabata, Kazuhito, Mayumi Suzuki, Masafumi Sugitani, et al.. (1991). ONO-5046, a novel inhibitor of human neutrophil elastase. Biochemical and Biophysical Research Communications. 177(2). 814–820. 313 indexed citations
4.
Ohno, Hiroyuki, et al.. (1989). Inhibitory Effects of ONO-3307 on Various Proteases and Tissue Thromboplastin In Vitro and on Experimental Thrombosis In Vivo. The Japanese Journal of Pharmacology. 51(4). 455–463. 2 indexed citations
5.
Ohno, Hiroyuki, et al.. (1989). Inhibitory effects of ONO-3307 on various proteases and tissue thromboplastin in vitro and on experimental thrombosis in vivo.. The Japanese Journal of Pharmacology. 51(4). 455–463. 12 indexed citations
6.
Inagawa, Tetsuji, et al.. (1983). Simplified immunoassays of prostaglandin E main metabolite in human urine.. PubMed. 11. 191–6. 10 indexed citations
7.
Gréen, K., et al.. (1983). Gas chromatographic — Mass spectrometric quantitation of 16,16-dimethyl-trans-Δ2-PGE1. Prostaglandins. 25(2). 225–235. 13 indexed citations
8.
Imaki, Katsuhiro, et al.. (1981). A convenient preparation of N-acylpyroglutamic acid.. Chemical and Pharmaceutical Bulletin. 29(9). 2699–2701. 6 indexed citations
9.
Imaki, Katsuhiro, et al.. (1981). Potent orally active inhibitors of angiotensin-converting enzyme (ACE).. Chemical and Pharmaceutical Bulletin. 29(8). 2210–2214. 10 indexed citations
10.
Imaki, Katsuhiro, et al.. (1976). The levels of main urinary metabolite of prostaglandin F1α and F2α in human subjects measured by radioimmunoassay. Prostaglandins. 12(2). 181–186. 7 indexed citations
11.
Imaki, Katsuhiro, et al.. (1975). Radioimmunoassay of main urinary metabolite of prostaglandin F2α. Prostaglandins. 10(6). 549–555. 12 indexed citations
12.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026